(Reuters) - U.S. health regulators on Wednesday approved Sanofi's diabetes drug Toujeo, a more potent follow-up to the French drugmaker's top-selling insulin product Lantus.
The Food and Drug Administration approved the once daily, long-acting basal insulin to treat adults with both type 1 and the far more prevalent type 2 diabetes.
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff17
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle20
16:38 Swift Energy completes $40 million sale of Louisiana asset13
03:00 Carrier incentives stir debate over 'rewarding' offshoring15